Latest Gossamer Bio News & Updates

See the latest news and media coverage for Gossamer Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gossamer Bio

Clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension

gossamerbio.com

Headquarters: San Diego, United States
Founded year: 2017
Company type: Public company
Number of employees: 120–200
Industry: Pharmaceuticals

Last updated October 28

Latest news about Gossamer Bio

In short: Gossamer Bio submitted seralutinib’s FDA application for pulmonary arterial hypertension.

Company announcements

October 1 Gossamer Bio

Gossamer Bio submits NDA for seralutinib in PAH

The submission marks years of clinical development, honoring patients and teams. Gossamer Bio remains focused on the next phase after this milestone.

September 23 Gossamer Bio

Gossamer Bio submits NDA to FDA for seralutinib

The submission targets pulmonary arterial hypertension, supported by Phase 3 PROSERA and Phase 2 TORREY trial data, marking the company's first NDA filing.

September 9 Gossamer Bio

Gossamer Bio executes 1-for-80 reverse stock split

The company aims to regain Nasdaq compliance by raising the minimum bid price requirement. Trading begins on September 11 under symbol GOSS with adjusted share ratios.

August 13 Gossamer Bio

Gossamer Bio announces second quarter 2026 financial results

Plans NDA submission for September 2026 after FDA meeting, reacquired global seralutinib rights from Chiesi, and reported Q2 net income of $16.9 million.

Media coverage

October 28 The Globe and Mail

Gossamer Bio Shareholders Approve Major Stock Issuance Plan

Gossamer Bio ( (GOSS)) has issued an announcement. At a special meeting held on October 27, 2026, Gossamer Bio stockholders approved a proposal under Nasdaq...

October 20 The Cardiology Advisor

Seralutinib New Drug Application Submitted to FDA for PAH

Gossamer Bio has submitted a New Drug Application to the FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH).

October 7 Rare Disease Advisor

Seralutinib New Drug Application Submitted to FDA for PAH

Gossamer Bio has submitted a New Drug Application to the FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH).

September 23 The Globe and Mail

Gossamer Bio Files First NDA for Seralutinib PAH Drug

Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

Never miss news about Gossamer Bio

Track Gossamer Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gossamer Bio competitors & trending companies

Browse news for competitors to Gossamer Bio and other trending companies.